Skip to main content
. 2020 Dec 1;10:20896. doi: 10.1038/s41598-020-77898-y

Figure 1.

Figure 1

(a) Kaplan–Meier plot for progression-free survival (PFS) of patients who received eribulin as a first-line therapy, and second or later-line therapy. 95% CI, confidence interval. HR, hazard ratio. (b) Kaplan–Meier plot for overall survival (OS) of patients who received eribulin as a first-line therapy, and second or later-line therapy. 95% CI, confidence interval. HR, hazard ratio.